|
Chairman and Chief Executive Officer
Nutra Pharma Corporation
Rik J. Deitsch has been the President,
Chief Executive Officer and a Director of
the Company since November 7, 2002. From
February 1998 through November 2002, Mr.
Deitsch served as the President of NDA Consulting
Inc., a biotechnology research group that
provided consulting services to the pharmaceutical
industry. NDA Consulting specialized in
the research of peptides derived from Cone
Snail venom, Cobra venom and Gila Monster
venom. Mr. Deitsch holds both a B.S. in
Chemistry and an M.S. in Biochemistry from
Florida Atlantic University and has conducted
clinical and laboratory research in collaboration
with scientists at Duke University Medical
Center and the Cleveland Clinic . Mr. Deitsch
is an adjunct professor and teaches several
courses for Florida Atlantic University's
College of Business and Continuing Education
Department. |
| |
|
| |
|
|
Interim President
ReceptoPharm, Inc.
Harold H. Rumph has been a Director of the Company since March of 2003
and brings with him a career devoted to technical
sales and marketing. From 1988 to 2003 he
was founder and owner of a high tech business
providing computerized scheduling services
to the construction industry. From 1986
to 1988, Mr. Rumph was Director of Sales
and Marketing for JE Research, Inc. From
1980 to 1986 he was a founder, President,
and Director of Biogenix, Inc. This company
was involved in the development, manufacturing,
and marketing of in-hospital bedside and
ambulatory Patient Monitoring Systems. Biogenix
was also involved with research and development
of antiviral peptides from cobra venoms,
including clinical trials under FDA-issued
Investigational New Drug applications. Prior
to the above Mr. Rumph led sales teams and
was responsible for marketing at Harris
Communications, Harris Computers, Memorex
Corporation, Xerox Corporation, Cincinnati
Milacron, Amdahl Corporation, RCA Computers,
and IBM. Mr. Rumph received his BS degree
from the United States Naval Academy. |
| |
|
| |
|
| |
Director
Dr. Lonky is board certified in internal
medicine, pulmonary and critical care medicine.
As a National Institutes of Health post
doctoral fellow and faculty member at the
University of California, San Diego, he
spearheaded a research team studying the
cellular and biochemical mechanisms of lung
injury. He has published over a dozen articles
in the peer-reviewed literature in this
field. His practice involves the evaluation
and treatment of patients with toxic exposures
as well as patients with lung disease, and
he has co-authored the book Invisible Killers,
The truth about environmental genocide.
From 1990-2006 he served as Chief Medical
Officer of a medical device company that
developed diagnostic products for the early
diagnosis of cervical and oral cancer. In
that role, his duties included the direction
of clinical research and the ultimate clearance
of three new diagnostic devices by the U.S.
Food and Drug Administration (FDA). Dr.
Lonky has published numerous articles in
the peer-reviewed literature in the area
of cellular physiology and its relation
to cervical and oral cancer detection. Since
Early 2007 he has been a Board Member of
Histologix, LLC, a company that is bringing
innovative biopsy tools to the medical marketplace.
Dr. Lonky is specifically involved with
the regulatory clearances of these novel
devices for use on various tissue surfaces.
Dr. Lonky earned his B.S. degree at St.
Lawrence University, his M.D. from the State
University of New York, Downstate, and his
M.B.A. from Pepperdine University.
|
| |
|
| |
|
|
Director
Garry R. Pottruck, 53 years of age, has been a Principal in the accounting and consulting firm, Argy, Wiltse & Robinson, PC ("Argy"), headquartered in McLean, Virginia, since October 2005. From July 1997 through October 2005 when that company was acquired by Argy, he was managing partner in the certified public accounting firm, Friedberg & Pottruck, PA, located in Deerfield Beach, Florida. Friedberg & Pottruck specialized in providing accounting, tax and consulting services to physician practices.
Mr. Pottruck held financial executive positions with several companies, both public and private, from 1984 through 1994, including more than three years as Chief Accounting Officer/Controller at Scopas Technology Company, Inc., a NASDAQ listed, development stage biotechnology research and development organization.
Prior to 1984, Mr. Pottruck worked for public accounting firms after graduating with a B.S. Degree in Accounting from the C.W. Post School of Professional Accountancy at Long Island University in 1979. He is currently a member of both the Florida and American Institutes of Certified Public Accounting, and is licensed as a Certified Public Accountant in both Missouri and Florida. |
|
|
| |
|
Read about Jeff Gottfurcht, the first rheumatoid arthritis sufferer to conquer Everest, in Musculoskeletal Health– a special section of the Washington Post. |
|
|
|
|
|
|
| |
|
| Click
here to learn more about Nyloxin, our over-the-counter treatment for moderate to severe chronic pain. |
|
|
|
|
| |
|
|
| |
|